TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03141372

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Void Trial using Foley catheter
Description: A void trial is a test to ensure that a subject does not have urinary retention after a surgical procedure. In an autofill void trial, the subject is allowed to void after surgery and the amount of resulting urine and the amount of urine still remaining in the bladder are measured. In a backfill void trial, water is instilled into the bladder, the foley is removed, and the subject is then allowed to urinate. Again, the amount of urine resulting and the amount of urine still in the bladder are measured.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Void Trial using Foley catheter
Description: A void trial is a test to ensure that a subject does not have urinary retention after a surgical procedure. In an autofill void trial, the subject is allowed to void after surgery and the amount of resulting urine and the amount of urine still remaining in the bladder are measured. In a backfill void trial, water is instilled into the bladder, the foley is removed, and the subject is then allowed to urinate. Again, the amount of urine resulting and the amount of urine still in the bladder are measured.
Study: NCT00261326

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: simvastatin
Description: 80 mg once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: calcium tablets once daily
Study: NCT00814905

Intervention type: DRUG
Group type: OTHER
Intervention: Ampicillin gentamicin clindamycin
Description: one dose of ampicillin 2 grams IV, gentamicin 1.5 mg/kg IV, clindamycin 900 mg IV and then saline infusions instead of antibiotics until they are afebrile for 24 hours ( they will receive saline infusions instead of antibiotics)

Intervention type: DRUG
Group type: OTHER
Intervention: ampicillin gentamicin clindamycin
Description: ampicillin 2 g IV every 6 hours, gentamicin 1.5mg/kg every 8 hours, and clindamycin 900 mg IV every 8 hours until the patient has been afebrile for 24 hours
Study: NCT03963336

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LMWH
Description: Subcutaneous LMWH 1mg/kg/day for 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acetazolamide
Description: Carbonic anhydrase inhibitor 1-2g/day for 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acetazolamide
Description: Carbonic anhydrase inhibitor 1-2g/day for 6 months
Study: NCT01850095

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dorspirenone/ethynil estradiol
Study: NCT03525730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic Acid
Description: Valproic acid (enteric) 30mg/kg, divided over 2 doses per day, orally on day 1-14.
Study: NCT00946842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: Participants will receive phase II clinical study tablet formulation of TMC207 100 mg as a single oral dose with food on Day 1, Day 30 and Day 58.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: Participants will receive phase II clinical study tablet formulation of TMC207 100 mg as a single oral dose with food on Day 1, Day 30 and Day 58.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: Participants will receive phase II clinical study tablet formulation of TMC207 100 mg as a single oral dose with food on Day 1, Day 30 and Day 58.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: Participants will receive phase II clinical study tablet formulation of TMC207 100 mg as a single oral dose with food on Day 1, Day 30 and Day 58.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: Participants will receive phase II clinical study tablet formulation of TMC207 100 mg as a single oral dose with food on Day 1, Day 30 and Day 58.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: Participants will receive phase II clinical study tablet formulation of TMC207 100 mg as a single oral dose with food on Day 1, Day 30 and Day 58.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: Participants will receive newly developed tablet formulation with fine particle size distribution of TMC207 100 mg as a single oral dose with food on Day 1, Day 30 and Day 58.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: Participants will receive newly developed tablet formulation with fine particle size distribution of TMC207 100 mg as a single oral dose with food on Day 1, Day 30 and Day 58.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: Participants will receive newly developed tablet formulation with fine particle size distribution of TMC207 100 mg as a single oral dose with food on Day 1, Day 30 and Day 58.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: Participants will receive newly developed tablet formulation with fine particle size distribution of TMC207 100 mg as a single oral dose with food on Day 1, Day 30 and Day 58.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: Participants will receive newly developed tablet formulation with fine particle size distribution of TMC207 100 mg as a single oral dose with food on Day 1, Day 30 and Day 58.
Study: NCT00002734

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: lutetium Lu 177 monoclonal antibody CC49

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: yttrium Y 90 monoclonal antibody CC49
Study: NCT00946842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: Participants will receive newly developed tablet formulation with fine particle size distribution of TMC207 100 mg as a single oral dose with food on Day 1, Day 30 and Day 58.
Study: NCT03525730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic Acid
Description: Valproic acid (enteric) 30mg/kg, divided over 2 doses per day, orally on day 1-14.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrimethamine
Description: Pyrimethamine 200mg once daily (QD) orally on day 1 and 100mg on day 2-14.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrimethamine
Description: Pyrimethamine 200mg once daily (QD) orally on day 1 and 100mg on day 2-14.
Study: NCT03021694

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Testing of micellar casein, blended micellar casein and native whey, versus native whey to determine post-ingestion aminoacidemia, glycemia, and insulinemia in young adult men

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Testing of micellar casein, blended micellar casein and native whey, versus native whey to determine post-ingestion aminoacidemia, glycemia, and insulinemia in young adult men

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Testing of micellar casein, blended micellar casein and native whey, versus native whey to determine post-ingestion aminoacidemia, glycemia, and insulinemia in young adult men
Study: NCT03563846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RP-G28
Description: RP-G28 is a purified galacto-oligosaccharide (GOS) product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RP-G28
Description: RP-G28 is a purified galacto-oligosaccharide (GOS) product
Study: NCT01135628

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Auxiliary Treatment
Description: Lactobacillus reuteri, 1 tablet bid, each of 100,000,000 FCU for 6 months

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Hyperproteic and fiber-rich diet
Description: Hyperproteic diet consisting in 1.5 gr/kg of protein per day Fiber-rich diet
Study: NCT00946842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: Participants will receive newly developed tablet formulation with coarse particle size distribution of TMC207 100 mg as a single oral dose with food on Day 1, Day 30 and Day 58.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: Participants will receive newly developed tablet formulation with coarse particle size distribution of TMC207 100 mg as a single oral dose with food on Day 1, Day 30 and Day 58.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: Participants will receive newly developed tablet formulation with coarse particle size distribution of TMC207 100 mg as a single oral dose with food on Day 1, Day 30 and Day 58.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: Participants will receive newly developed tablet formulation with coarse particle size distribution of TMC207 100 mg as a single oral dose with food on Day 1, Day 30 and Day 58.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: Participants will receive newly developed tablet formulation with coarse particle size distribution of TMC207 100 mg as a single oral dose with food on Day 1, Day 30 and Day 58.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: Participants will receive newly developed tablet formulation with coarse particle size distribution of TMC207 100 mg as a single oral dose with food on Day 1, Day 30 and Day 58.
Study: NCT01135628

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Hyperproteic and fiber-rich diet
Description: Hyperproteic diet consisting in 1.5 gr/kg of protein per day Fiber-rich diet

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Hyperproteic and fiber-rich diet
Description: Hyperproteic diet consisting in 1.5 gr/kg of protein per day Fiber-rich diet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitazoxanide
Description: Nitazoxanide tablets 400 mg, bid, orally for 6 months
Study: NCT03383419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epclusa
Description: If and when these recipients develop confirmed viremia by HCV PCR, Epclusa® therapy will be administered for a 12-week course.
Study: NCT00344214

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tri-focal cognitive behavioral therapy - social skills training (CBTSS) counseling program
Description: This condition is a Theory-Based Counseling Program. The program will involve nine 90-minute face-to-face counseling sessions that use CBT and strategies associated with social cognitive theory. The theory addresses three treatment domains, including mood regulation, reduction/cessation of meth use, and reduction of high risk sexual practices.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Standard care involves nine weekly, face-to-face individual counseling sessions that provide standard care in relation to sexual risk, methamphetamine use, and depression. The sexual risk component is a modified version of Project RESPECT 1 (CDC, Atlanta) that focuses on educational materials and personal risk appraisal. The meth component is a modified version of the 12-step drug abstinence program developed by the National Institute of Alcohol Abuse and Alcoholism (NIAAA) (Project MATCH). The depression component is an educational approach based primarily on materials provided by the National Alliance on Mental Illness (NAMI) and the National Institute of Mental Health (NIMH).
Study: NCT00831623

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Radiation
Description: 3 Cobalt Gray Equivalent (CGE) /Day to isocenter, one treatment per day, 5 days per week for 20 treatments (=60 CGE to isocenter/20 fractions)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton
Description: As above
Study: NCT00946842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment D
Description: Participants will receive phase II clinical study tablet formulation of TMC207 100 mg as a single oral dose without food on Day 1, Day 30 and Day 58.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment D
Description: Participants will receive phase II clinical study tablet formulation of TMC207 100 mg as a single oral dose without food on Day 1, Day 30 and Day 58.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment D
Description: Participants will receive phase II clinical study tablet formulation of TMC207 100 mg as a single oral dose without food on Day 1, Day 30 and Day 58.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment D
Description: Participants will receive phase II clinical study tablet formulation of TMC207 100 mg as a single oral dose without food on Day 1, Day 30 and Day 58.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment D
Description: Participants will receive phase II clinical study tablet formulation of TMC207 100 mg as a single oral dose without food on Day 1, Day 30 and Day 58.
Study: NCT00773695

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aromatase Inhibitor
Description: Participants will receive aromatase inhibitor therapy, at a dose per investigator discretion, once daily for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatase Inhibitor
Description: Participants will receive aromatase inhibitor therapy, at a dose per investigator discretion, once daily for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered at a dose of 15 mg/kg as IV infusion every 3 weeks (or 10 mg/kg every other week in participants receiving weekly paclitaxel), for 24 weeks.
Study: NCT00946842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment D
Description: Participants will receive phase II clinical study tablet formulation of TMC207 100 mg as a single oral dose without food on Day 1, Day 30 and Day 58.
Study: NCT00773695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered at a dose of 15 mg/kg as IV infusion every 3 weeks (or 10 mg/kg every other week in participants receiving weekly paclitaxel), for 24 weeks.
Study: NCT00946842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment E
Description: Participants will receive newly developed tablet formulation with fine particle size distribution of TMC207 100 mg as a single oral dose without food on Day 1, Day 30 and Day 58.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment E
Description: Participants will receive newly developed tablet formulation with fine particle size distribution of TMC207 100 mg as a single oral dose without food on Day 1, Day 30 and Day 58.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment E
Description: Participants will receive newly developed tablet formulation with fine particle size distribution of TMC207 100 mg as a single oral dose without food on Day 1, Day 30 and Day 58.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment E
Description: Participants will receive newly developed tablet formulation with fine particle size distribution of TMC207 100 mg as a single oral dose without food on Day 1, Day 30 and Day 58.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment E
Description: Participants will receive newly developed tablet formulation with fine particle size distribution of TMC207 100 mg as a single oral dose without food on Day 1, Day 30 and Day 58.
Study: NCT02804061

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NELIP
Study: NCT00946842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment E
Description: Participants will receive newly developed tablet formulation with fine particle size distribution of TMC207 100 mg as a single oral dose without food on Day 1, Day 30 and Day 58.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment F
Description: Participants will receive newly developed tablet formulation with coarse particle size distribution of TMC207 100 mg as a single oral dose without food on Day 1, Day 30 and Day 58

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment F
Description: Participants will receive newly developed tablet formulation with coarse particle size distribution of TMC207 100 mg as a single oral dose without food on Day 1, Day 30 and Day 58

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment F
Description: Participants will receive newly developed tablet formulation with coarse particle size distribution of TMC207 100 mg as a single oral dose without food on Day 1, Day 30 and Day 58

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment F
Description: Participants will receive newly developed tablet formulation with coarse particle size distribution of TMC207 100 mg as a single oral dose without food on Day 1, Day 30 and Day 58

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment F
Description: Participants will receive newly developed tablet formulation with coarse particle size distribution of TMC207 100 mg as a single oral dose without food on Day 1, Day 30 and Day 58

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment F
Description: Participants will receive newly developed tablet formulation with coarse particle size distribution of TMC207 100 mg as a single oral dose without food on Day 1, Day 30 and Day 58
Study: NCT00773695

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicine
Description: Participants will receive epirubicine at a dose of 100 mg/m\^2 as IV infusion every 3 weeks for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicine
Description: Participants will receive epirubicine at a dose of 100 mg/m\^2 as IV infusion every 3 weeks for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluorouracil (5FU)
Description: Participants will receive 5FU at a dose of 600 mg/m\^2 as IV infusion every 3 weeks for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil (5FU)
Description: Participants will receive 5FU at a dose of 600 mg/m\^2 as IV infusion every 3 weeks for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Participants will receive cyclophosphamide at a dose of 600 mg/m\^2 as IV infusion every 3 weeks for 12 weeks.
Study: NCT04389853

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Flexible ureteroscopy
Description: Retograde intrarenal surgery (RIRS) has gained much popularity especially when the role of SWL, in management of LPS, has been significantly diminished in the few last years5. RIRS is dependent mainly on flexible ureteroscopy (fURS). fURS increases the quality and performance of upper urinary tract exploration, allowing for the treatment of the majority of stones at all sites. Moreover, it is associated with no risk of renal parenchymal injuries and a very low risk of bleeding.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mini-percutaneous nephrolithotomy
Description: PCNL has regained popularity thanks to the possibility of using reduced calibers and modern technology, which has reduced the complications without compromising the stone clearance, and more efficient intracorporeal lithotripter modalities. However, PCNL is still a challenging surgical technique and can be associated with significant complications that may compromise its efficacy. In the present time, we have available calibers ranging from 4.8 to 30 French. Many reports advocate that morbidity after PCNL may be reduced by recent modifications, such as mini-PCNL (miniperc). One meta-analysis of mini-PCNL and conventional PCNL demonstrated that mini-PCNL had a greater safety profile with similar stone free rates (SFRs).
Study: NCT00799383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium and Vitamin D
Description: Calcium carbonate 625mg and vitamin D 200IU will be administered, orally, twice a day for a nine-month period.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00773695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Participants will receive cyclophosphamide at a dose of 600 mg/m\^2 as IV infusion every 3 weeks for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Participants will receive paclitaxel at a dose of 80 mg/m\^2 as IV infusion every week for 12 weeks.
Study: NCT03385681

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tailored Educational Intervention
Description: The intervention will be a one-day seminar for nurses working at the units, with lectures and workshops with main focus on the subjects showing the lowest pediatric pain management competence. In addition, there will be clinical supervision in pediatric postoperative pain management (two or three days per unit). The intervention will be conducted by two experts (nurse and physician) in pediatric postoperative pain management. After the intervention there will be different reminders every week for the first month, and then every month (in different forms) about pediatric pain management during six months of time.
Study: NCT03094182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron Isomaltoside 1000
Description: Randomly selected patients of the monofer group are given 1000mg of iron isomaltoside, which are mixed in 100ml normal saline, intravenous after induction for 30 minutes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Randomly selected patients in the control group receive an equivalent volume of normal saline as a placebo.
Study: NCT00773695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Participants will receive paclitaxel at a dose of 80 mg/m\^2 as IV infusion every week for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Participants will receive docetaxel at a dose of 100 mg/m\^2 as IV infusion every 3 weeks for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Participants will receive docetaxel at a dose of 100 mg/m\^2 as IV infusion every 3 weeks for 12 weeks.
Study: NCT00603291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorcaserin 10 mg once daily (QD)
Description: Lorcaserin 10 mg tablet each morning and placebo tablet each evening for a duration of 52 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorcaserin 10 mg twice a day (BID)
Description: Lorcaserin 10 mg tablet each morning and evening for a duration of 52 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Matching placebo tablet each morning and evening for a duration of 52 weeks.